VolitionRx Limited Net Income (Loss) Available to Common Stockholders, Basic
VolitionRx Limited (VNRX) reported Net Income (Loss) Available to Common Stockholders, Basic of $14.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-13
- VolitionRx Limited net income (loss) available to common stockholders, basic for the quarter ending 2024-12-31 was -$5.79M.
- VolitionRx Limited net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$5.82M.
- VolitionRx Limited net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was -$6.99M.
- VolitionRx Limited net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$8.37M.
- VolitionRx Limited net income (loss) available to common stockholders, basic for fiscal 2024 was -$26.97M.
- VolitionRx Limited net income (loss) available to common stockholders, basic for fiscal 2023 was -$35.32M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.00M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | -$5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$11.61M derived: sum of 2 quarters · filed 2025-03-31 | -$18.60M derived: sum of 3 quarters · filed 2025-03-31 | -$26.97M 10-K · filed 2025-03-31 |
| 2024-09-30 | -$5.82M 10-Q · filed 2024-11-14 | -$12.81M derived: sum of 2 quarters · filed 2024-11-14 | -$21.17M 10-Q · filed 2024-11-14 | -$29.87M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | -$6.99M 10-Q · filed 2024-08-14 | -$15.35M 10-Q · filed 2024-08-14 | -$24.05M derived: sum of 3 quarters · filed 2025-03-31 | -$32.42M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | -$8.37M 10-Q · filed 2024-05-13 | -$17.07M derived: sum of 2 quarters · filed 2025-03-31 | -$25.44M derived: sum of 3 quarters · filed 2025-03-31 | -$34.91M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | -$8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$17.07M derived: sum of 2 quarters · filed 2025-03-31 | -$26.54M derived: sum of 3 quarters · filed 2025-03-31 | -$35.32M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$8.37M 10-Q · filed 2024-11-14 | -$17.84M derived: sum of 2 quarters · filed 2024-11-14 | -$26.62M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$9.47M 10-Q · filed 2024-08-14 | -$18.25M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$8.78M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |